Grant ID RP170619
Awarded On August 16, 2017
Title An Unexpected Oncometabolic Axis: Exposing Novel Regulators of Cardiac Remodeling in Leukemia
Program Academic Research
Award Mechanism High Impact/High Risk
Institution/Organization The University of Texas Health Science Center at Houston
Principal Investigator/Program Director Heinrich Taegtmeyer
Cancer Sites Leukemia
Contracted Amount $199,744
Lay Summary

Acute myeloid leukemia (AML) affects 20,000 Americans annually and is the most common cancer in children. Improved treatments have increased patient survival, but despite these efforts survivors have a five-fold higher risk for developing heart failure. Recent advances in clinical and basic research studies have found that deteriorating cardiovascular events occur in survivors independent of the type of cancer treatment. This underscores the need for innovative therapeutic strategies to target leukemia cells and to ultimately protect the heart. Specific metabolic activities provide benefits to cancer cells and drive tumor growth. Two genes called IDH1 and IDH2 are mutated in 20% of AML cases...

Read More